...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical & Translational Endocrinology >Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
【24h】

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects

机译：探索糖尿作为减轻体重和脂肪量的一种机制。依托格列净和依格列净在健康肥胖者中的初步研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine and improve blood glucose in Type 2 diabetes mellitus. Glycosuria provides an energy and osmotic drain that could alter body composition. We therefore conducted a pilot study comparing the effects on body composition of two SGLT2 inhibitors, remogliflozin etabonate (RE) 250?mg TID ( n ?=?9) and sergliflozin etabonate (SE) (1000?mg TID) ( n ?=?9), with placebo ( n ?=?12) in obese non-diabetic subjects. Both drugs were well tolerated during 8 weeks of dosing, and the most common adverse event was headache. No urinary tract infections were observed, but there was one case of vaginal candidiasis in the RE group. As expected, RE and SE increased urine glucose excretion, with no change in the placebo group. All the subjects lost weight over 8 weeks, irrespective of treatment assignment. There was a reduction in TBW measured by D 2 O dilution in the RE group that was significantly greater than placebo (1.4?kg, p ?=?0.029). This was corroborated by calculation of fat-free mass using a quantitative magnetic resonance technique. All but one subject had a measurable decrease in fat mass. There was significant between-subject variability of weight and fat loss, and no statistically significant differences were observed between groups. Despite a lack of a difference in weight and fat mass loss, the leptin/adiponectin ratio, a measure of insulin resistance, was significantly decreased in the RE group when compared to placebo and SE, suggesting that this SGTL-2 inhibitor may improve metabolic health independent of a change in fat mass.
机译：钠依赖性葡萄糖共转运蛋白2（SGLT2）抑制剂可增加2型糖尿病患者尿液中的葡萄糖排泄并改善血糖。糖尿能提供能量和渗透排泄，可能会改变人体成分。因此，我们进行了一项初步研究，比较了两种SGLT2抑制剂对人体的影响：雷莫列净依替贝酸盐（RE）250 mg mg TID（n = 9）和西格列净依替贝酸盐（SE）（1000 mg mg TID）（n？=？ 9），在肥胖的非糖尿病受试者中使用安慰剂（n≥12）。两种药物在服药8周后耐受良好，最常见的不良事件是头痛。没有观察到尿路感染，但是在RE组中有1例阴道念珠菌病。正如预期的那样，RE和SE增加了尿液葡萄糖的排泄，而安慰剂组没有变化。不论治疗分配如何，所有受试者均在8周内减肥。在RE组中，通过D 2 O稀释测定的TBW降低明显大于安慰剂（1.4？kg，p？=？0.029）。通过使用定量磁共振技术计算无脂肪质量来证实这一点。除一名受试者外，所有受试者的脂肪量均明显减少。受试者的体重和脂肪损失之间存在显着差异，并且两组之间没有统计学上的显着差异。尽管在体重和脂肪质量损失方面没有差异，但与安慰剂和SE相比，RE组中的瘦素/脂联素比率（一种衡量胰岛素抵抗的指标）显着降低，表明该SGTL-2抑制剂可改善代谢健康与脂肪量的变化无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号